|
Mr. Greg Nordal Joins Advisory Committee
FOR IMMEDIATE RELEASE
February 11, 2002
Burlington, Ontario
THE JENEX CORPORATION ("Jenex" or the "Corporation")
(CDNX - JEN), is pleased to announce the addition of Mr.
Greg Nordal to its Corporate Advisory Committee. Mr. Nordal
brings valuable business development experience and a strong
history of professional achievement to the Corporation. He
becomes the 6th member of the Corporation's Accomplished Advisory
Committee (see www.jenexcorp.com). The Advisory Committee
is an integral part of the Corporation's strategy to seek
experienced professional advisors to assist the Company in
achieving its corporate goals.
Mr. Nordal joined Dun & Bradstreet Canada in July of 1997
and is the company's President and Chief Operating Officer.
The Dun & Bradstreet Corporation is the world's leading
provider of business information products and decision support
services for risk management, marketing and supply chain management
solutions. In addition to his Canadian responsibilities, Mr.
Nordal has served on Dun & Bradstreet's Leadership team
for the Asia-Pacific, Canada, Latin America Region.
Prior to joining Dun & Bradstreet, Mr. Nordal spent 13
years in the healthcare industry working in Executive capacities
focused on growth, business diversification and general management.
About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation has
developed and patented a thermal therapeutic device for the
prevention of cold sores. Patents in fifteen countries, including
the United States, Canada, Australia, and the E.E.C protect
the technology. A license to market from regulatory, Therapeutic
Products Programme (TPP), in Canada has been received to market
their thermal therapy device, over-the-counter (OTC) with
the claim "For prevention and relief of the symptoms
of herpes labialis (cold sores), such as blistering, lesions,
inflammation, and discomfort. Also helps alleviate the embarrassment
that is typically associated with herpes labialis (cold sore)
outbreaks". A medical device number has been issued
by TPP, in accordance with Medical Device Regulations. Jenex
is the first company to receive clearance to market from a
significant regulatory body to make the prevention
claim for cold sores.
The Corporation is currently seeking clearance from FDA to
make a similar marketing claim in the United States. Management
of the Corporation expects a response from the FDA in the
2nd quarter of 2002. Regulatory approvals are being pursued
in all European countries and Australia.
Jenex is now seeking a strategic corporate partner to license
and commercialize their thermal therapy technology. Several
Multi-National Companies have signed Confidentiality Agreements
and are in various stages of due diligence.
The HSV-1 virus that causes cold sores, is endemic in North
America, and is estimated to affect 80% of the population.
As the only product clinically proven to prevent the outbreak
of cold sores, the Corporation's thermal therapy product has
the potential to dominate a large and underdeveloped market.
"Prevention is the Solution"
For further information, see www.jenexcorp.com or contact:
Michael A. Jenkins, President
The Jenex Corporation
207 - 940 Sheldon Court
Burlington, Ontario
L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: Jenex@sprint.ca
|
